Clinical Trial Update: A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253 [Phase 3]

View source ↗

Summary

Phase 3 study assessing whether IL28B polymorphism influences response to Pegasys (pegylated interferon alfa-2a) in HBeAg-negative chronic hepatitis B; trial co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2015-07-10